Forbes Earnings Preview: Halozyme Therapeutics

Halozyme Therapeutics (HALO) is expected to book a narrower loss than a year ago when it reports fourth quarter earnings on Monday, February 25, 2013 with analysts expecting a loss of 15 cents per share, up from a loss of 18 cents per share a year ago.